Table 2.

Summary of treatment outcomes

	Total	Hydroxychloroquine	CDK4/6 inhibitor
	(n = 13)	(n = 8)	(n = 5)
Reason for treatment discontinuation
Disease progression	5 (38.5%)	2 (25.0%)	3 (50.0%)
Tumor-related AEs	5 (38.5%)	4 (50.0%)	1 (20.0%)
Treatment-related AEs	3 (23.1%)	2 (25.0%)	1 (20.0%)
Change in CA19-9
Declined over 30%	3 (23.1%)	1 (12.5%)	2 (40.0%)
Declined less than 30%	4 (30.8%)	4 (50.0%)	0 (0%)
Not expressed	3 (23.1%)	1 (12.5%)	2 (40.0%)
Unknown	3 (23.1%)	2 (25.0%)	1 (20.0%)
Treatment response
Progressive disease	9 (69.2%)	5 (62.5%)	4 (80.0%)
Stable disease	1 (7.7%)	1 (12.5%)	0 (0%)
Unknown	3 (23.1%)	2 (25.0%)	1 (20.0%)

Abbreviation: AEs adverse events